Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, Garrison LP

Diabetes care1 Feb 2011Cited by 50 (Europe PMC)

PMID21270189PMCIDPMC3024340DOI10.2337/dc10-1119PepBankPUB-21270189

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2D patients, weight-related quality of life total scores improved significantly with once-weekly exenatide from baseline.
In plain wordsIn T2D patients, weight-related quality of life improved with weekly exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight-related quality of life total score
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Weight-related quality of life total scores improved significantly in the exenatide once weekly and sitagliptin arms only;
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018901
02HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly exenatide improved weight-related quality of life total scores more than pioglitazone.
In plain wordsIn T2D patients, weekly exenatide improved weight-related quality of life more than pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight-related quality of life total score
Study
n: not reported in source
Comparator
Pioglitazone
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
the exenatide once weekly group experienced significantly greater improvement than the pioglitazone group in weight-related quality of life total scores and in several domain scores.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018902
03HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly exenatide improved several unnamed weight-related quality of life domains more than pioglitazone.
In plain wordsIn T2D patients, weekly exenatide improved several weight-related quality of life areas more than pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight-related quality of life domain scores
Study
n: not reported in source
Comparator
Pioglitazone
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
the exenatide once weekly group experienced significantly greater improvement than the pioglitazone group in weight-related quality of life total scores and in several domain scores.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018903
04HumanRandomized controlled trialEfficacy outcome
In T2D patients, health utility scores improved significantly from baseline with weekly exenatide.
In plain wordsIn T2D patients, health utility scores improved with weekly exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHealth utility
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Health utility scores improved significantly for exenatide once weekly and sitagliptin groups (P < 0.05) with no significant difference between the exenatide once weekly group and either comparison group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018904
05HumanRandomized controlled trialEfficacy outcome
In T2D patients, health utility improvement did not differ significantly between weekly exenatide and sitagliptin.
In plain wordsIn T2D patients, health utility improvement did not differ significantly between weekly exenatide and sitagliptin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHealth utility
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Health utility scores improved significantly for exenatide once weekly and sitagliptin groups (P < 0.05) with no significant difference between the exenatide once weekly group and either comparison group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018905
06HumanRandomized controlled trialEfficacy outcome
In T2D patients, health utility improvement did not differ significantly between weekly exenatide and pioglitazone.
In plain wordsIn T2D patients, health utility improvement did not differ significantly between weekly exenatide and pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHealth utility
Study
n: not reported in source
Comparator
Pioglitazone
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Health utility scores improved significantly for exenatide once weekly and sitagliptin groups (P < 0.05) with no significant difference between the exenatide once weekly group and either comparison group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018906
07HumanRandomized controlled trialEfficacy outcome
In T2D patients, global and domain well-being improvements did not differ significantly between weekly exenatide and sitagliptin.
In plain wordsIn T2D patients, well-being improvements did not differ significantly between weekly exenatide and sitagliptin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePsychological well-being global and domain scores
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
All groups experienced significant improvements on the psychological well-being global scale and all six domain scores, with no significant difference between the exenatide once weekly group and either comparator.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018907
08HumanRandomized controlled trialEfficacy outcome
In T2D patients, global and domain well-being improvements did not differ significantly between weekly exenatide and pioglitazone.
In plain wordsIn T2D patients, well-being improvements did not differ significantly between weekly exenatide and pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePsychological well-being global and domain scores
Study
n: not reported in source
Comparator
Pioglitazone
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
All groups experienced significant improvements on the psychological well-being global scale and all six domain scores, with no significant difference between the exenatide once weekly group and either comparator.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018908
09HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly exenatide improved treatment satisfaction total scores more than sitagliptin.
In plain wordsIn T2D patients, weekly exenatide improved treatment satisfaction more than sitagliptin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment satisfaction total score
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Quality of life · Whole body
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The exenatide once weekly group experienced greater improvement than the sitagliptin group in treatment satisfaction total scores.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
Report a problemFND-2127018910

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D patients, treatment satisfaction improved in all groups, including weekly exenatide and both active comparators.
In plain wordsIn T2D patients, treatment satisfaction improved in all groups, including weekly exenatide and both comparison treatments.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment satisfaction total score
Study
n = 491
Comparator
Baseline in each treatment group
Outcome group
Quality of life · Whole body
Source sentences
Summary
All groups experienced significant improvements in total diabetes treatment satisfaction scores.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2127018909
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D patients, psychological well-being global scores improved in all groups, including weekly exenatide, sitagliptin and pioglitazone.
In plain wordsIn T2D patients, overall psychological well-being improved from baseline in all groups, including weekly exenatide and both comparators.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePsychological well-being global scale
Study
n = 491
Comparator
Baseline in each treatment group
Outcome group
Quality of life · Whole body
Source sentences
Summary
All groups experienced significant improvements on the psychological well-being global scale and all six domain scores, with no significant difference between the exenatide once weekly group and either comparator.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2127018911
12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D patients, all six psychological well-being domain scores improved in all groups, including weekly exenatide, sitagliptin and pioglitazone.
In plain wordsIn T2D patients, all six well-being areas improved from baseline in all groups, including weekly exenatide and both comparators.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePsychological well-being domain scores
Study
n = 491
Comparator
Baseline in each treatment group
Outcome group
Quality of life · Whole body
Source sentences
Summary
All groups experienced significant improvements on the psychological well-being global scale and all six domain scores, with no significant difference between the exenatide once weekly group and either comparator.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week randomized, multicenter, double-dummy study, 491 subjects received 2 mg of exenatide once weekly or maximum daily doses of sitagliptin (100 mg) or pioglitazone (45 mg) on a background of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2127018912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.